PTGX 📈 Protagonist Therapeutics - Overview

Protagonist Therapeutics Inc, a biopharmaceutical company, focuses on developing innovative peptide-based treatments for various diseases, including hematology and blood disorders, as well as inflammatory and immunomodulatory conditions.

The company's pipeline includes Rusfertide (PTG-300), an injectable hepcidin mimetic that has shown promising results in phase 2 clinical trials for the treatment of polycythemia vera, a rare blood disorder characterized by an overproduction of red blood cells. Rusfertide aims to regulate iron levels in the body, which can help alleviate symptoms associated with this condition.

Another key drug candidate is JNJ-2113, an orally delivered investigational treatment designed to block biological pathways involved in inflammation. This drug has completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis, a chronic autoimmune condition that causes skin inflammation and scarring.

Additionally, Protagonist Therapeutics is developing PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist that has completed phase 2 clinical trials in patients with moderate to severe ulcerative colitis, a type of inflammatory bowel disease. PN-943 aims to reduce inflammation in the gut and promote healing.

The company has established strategic partnerships to advance its pipeline, including a license and collaboration agreement with Takeda to commercialize rusfertide, and a co-development agreement with JNJ Innovative Medicines for JNJ-2113.

Founded in 2006, Protagonist Therapeutics Inc is headquartered in Newark, California, and is committed to developing innovative treatments that address significant unmet medical needs. For more information, please visit their website at https://www.protagonist-inc.com.